- February 8, 2024Behind the numbers: 2023 patent litigation trends in the Western District of Texas
- January 2024Crack the Code: Evaluating Cyber Claim Exposure
- January 2024Considerations for D&O Insurance in light of the Changing Diversity, Equity, and Inclusion (DEI) Legal Landscape
- January 2024The Weight of Words
- First QuarterNew ANDA Cases
- January 2024The Robins Kaplan Insurance Insight June 2024
- First QuarterGeneric Launches
- January 3, 2024Navigating Class Actions After Papa John's Settlement Denial
- December 28, 2023Data Shows Most SEP Holders Send Pre-Suit Demand Letters - For Good Reason
- First QuarterANDA Approvals
- December 29, 2023Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
- Lawdragon:
In Conversation with Tara Sutton, Head of The Mass Tort Practice at Robins Kaplan - December 2023Advancement Proceedings: A Litigation Expense Your Client Might Not Have Anticipated
- December 2023Who Pays When You Fight Over a Trust?
- December 2023Can the Threat of Fees Discourage Unnecessary Fiduciary Disputes? Maybe...
- December 13, 2023Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
- December 7, 2023H. Lundbeck A/S v. Lupin Ltd.
- Fall 2023All Is Not Lost: Personal Jurisdiction in a Post-BMS World
- A New Era of Copyright Litigation in Hollywood
- E-Commerce Platform Liability for Trademark Infringement
- November 8, 2023Generative Artificial Intelligence, LLMs, And Fair Use After Warhol: The Copyright Office and Accountability
- November 7, 2023Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
- November 6, 2023Actelion Pharms. Ltd. v. Mylan Pharms. Inc.
- November 1, 2023Norwich Pharms., Inc. v. Becerra
- Fourth QuarterANDA Litigation Settlements
- Bausch Health Ireland Ltd. v. Padagis Israel Pharms. Ltd.
- Recent Litigation Disputes Involving Generative AI
- 2023 Bulletin - Third QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2023 Q3
- Third QuarterANDA Approvals
- Third QuarterANDA Litigation Settlements
- Third QuarterGeneric Launches
- Third QuarterNew ANDA Cases
- October 9, 2023Q&A: The Crossroads Where Generative AI Meets Copyright Law
- Fourth QuarterGeneric Launches
- Fourth QuarterNew ANDA Cases
- Fourth QuarterANDA Approvals
- Novartis Pharms. Corp. v. Alembic Pharms. Ltd.
- CMP Development, LLC v. Amneal Pharms. LLC
- Allergan USA, Inc. v. MSN Labs. Private Ltd.
- Takeda Pharms. U.S.A., Inc. v. Mylan Pharms., Inc.
- September 2023Walking the Razor’s Edge: Client Capacity and the Attorney-Client Relationship
- September 2023Meet Our Keynote Speaker: Journalist and New York Times Contributor Katie Engelhart
- September 2023Evenstad Family Trial Aftermath: Rule 408 May Not Be Used as a Sword and Shield
- September 8, 2023Zogenix, Inc. v. Apotex Inc.
- September 8, 2023Purdue Pharma L.P. v. Accord Healthcare Inc.
- Colorado Expands Antitrust Protection
- July 18, 2023Copyright: Rights Even Heroes Can't Protect
- UCB, Inc. v. Annora Pharma Priv. Ltd.
- Taiho Pharm. Co., Ltd. v. Eugia Pharma Specialties Ltd.
- August 2023Minnesota Passes Survivorship Bill, Expanding Justice for Victims of Medical Malpractice and Wrongful Death
Insights
Conference of Tribal Lending Commissioners
Innovative Work Models: Unlocking Flexibility and Success at Law Firms
Indirect Purchaser Plaintiffs Secure Class Certification in Hard Disk Drive Suspension Assemblies Antitrust Litigation
Robins Kaplan Files Lawsuit Alleging Pfizer and Others Failed to Warn of Brain Tumor Risks Linked to Contraceptive Depo-Provera
